What is Linzess Used For?
Linzess (linaclotide) is FDA-approved for treating three specific conditions: irritable bowel syndrome with constipation (IBS-C) in adults at 290 mcg daily, chronic idiopathic constipation (CIC) in adults at 72-145 mcg daily, and functional constipation in children ages 6-17 years at 72 mcg daily 1.
FDA-Approved Indications
Linzess is a guanylate cyclase-C agonist that works by increasing intestinal fluid secretion and accelerating gastrointestinal transit 2. The medication has three distinct approved uses:
For Adults with IBS-C
- Dosage: 290 mcg once daily
- Mechanism: Beyond improving bowel movements, linaclotide has been demonstrated to improve abdominal symptoms of bloating, discomfort, and pain in IBS-C trials 2
- Efficacy: In clinical trials, 34% of patients met the FDA responder endpoint (improvement in both abdominal pain and bowel movements) compared to 19% with placebo 3
For Adults with Chronic Idiopathic Constipation
- Dosage: 145 mcg once daily (or 72 mcg based on individual tolerability)
- Evidence: The 2023 AGA-ACG guidelines provide a strong recommendation for linaclotide use in adults with CIC who do not respond to over-the-counter agents, with moderate certainty of evidence 2
- Benefits: Increases complete spontaneous bowel movements by 1.37 per week, improves stool consistency, and increases global relief rates (RR 1.96) 2
For Pediatric Patients (Ages 6-17) with Functional Constipation
- Dosage: 72 mcg once daily
- Recent approval: Based on a 2024 phase 3 trial showing significant improvement in spontaneous bowel movement frequency (increase of 2.22 SBMs/week vs 1.05 with placebo) 4
How Linaclotide Works
Linaclotide is a 14-amino acid peptide that activates guanylate cyclase-C receptors on intestinal epithelial cells, resulting in:
- Increased cyclic GMP production
- Enhanced chloride and bicarbonate secretion into the intestinal lumen
- Increased intestinal fluid and accelerated GI transit 2
Unique analgesic mechanism: Linaclotide also produces extracellular cGMP that inhibits colonic nociceptors, directly reducing abdominal pain independent of its effects on constipation 5. This dual mechanism makes it particularly useful for patients with both constipation and abdominal pain.
Clinical Use Algorithm
When to use linaclotide:
- First-line for IBS-C in adults, especially when abdominal pain/bloating is prominent
- Second-line for CIC in adults after failure of OTC laxatives (fiber, polyethylene glycol, magnesium oxide)
- Can be used as replacement or adjunct to OTC agents 2
- Consider in pediatric functional constipation (ages 6-17) when conventional therapy inadequate 4
Administration requirements:
- Take on empty stomach at least 30 minutes before first meal of the day 2
- Swallow capsule whole, or can open and mix with applesauce or water for those unable to swallow 1
Important Safety Considerations
Contraindications:
- Absolute: Children under 2 years of age (risk of severe dehydration and death) 1
- Known or suspected mechanical GI obstruction 2
Common adverse effects:
- Diarrhea is the most common side effect (16.3% vs 2.3% placebo in IBS-C trials) 3
- Most diarrhea is mild to moderate; only 4.7% discontinued due to diarrhea in one study 2
- If severe diarrhea occurs, stop medication and contact healthcare provider 1
Quality of life impact: In treatment-resistant chronic constipation patients previously failing magnesium oxide, linaclotide significantly improved quality of life scores (JPAC-QOL change of -0.89, p<0.001) 6.
Duration of Treatment
The drug label does not provide a treatment duration limit, though clinical trials evaluated 12-week periods 2. In real-world practice, the most common reasons for discontinuation over the first year were loss of efficacy and insurance coverage barriers—not adverse events 2.